Advertisement
Screener

Cingulate Inc. (CING) Graph

CING Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $1.49M; Selling, general and administrative $3.93M; Net income -$5.87M.
  • 2026-03-31: Research and development $2.18M; Selling, general and administrative (m); Net income -$9.31M.
  • 2025-12-31: Research and development $2.00M*; Selling, general and administrative (m); Net income -$6.27M*.
  • 2025-09-30: Research and development $2.85M; Selling, general and administrative (m); Net income -$7.34M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentSelling, general and administrativeNet income
2026-06-30$1.49M$3.93M-$5.87M
2026-03-31$2.18M(m)-$9.31M
2025-12-31$2.00M*(m)-$6.27M*
2025-09-30$2.85M(m)-$7.34M
2025-06-30$2.70M$1.95M-$4.98M
2025-03-31$2.22M(m)-$3.85M
2024-09-30$1.43M(m)-$4.13M
2024-06-30$1.88M(m)-$3.23M
2024-03-31$1.81M(m)-$2.97M
2023-09-30$3.92M(m)-$5.98M
2023-06-30$4.46M(m)-$6.62M
2023-03-31$2.13M(m)-$4.00M
2022-09-30$2.12M(m)-$4.03M
2022-06-30$2.18M(m)-$4.04M
2022-03-31$2.76M(m)-$5.00M
2021-09-30$5.79M(m)-$15.29M
2021-06-30$793.59K(m)-$1.43M
2021-03-31$562.52K(m)-$1.33M

Revenue and expense 6 month

Period endResearch and developmentSelling, general and administrativeNet income
2026-06-30$3.67M$9.67M-$15.18M
2025-06-30$4.92M$3.43M-$8.84M
2024-06-30$3.69M(m)-$6.18M
2023-06-30$6.58M(m)-$10.62M
2022-06-30$4.94M(m)-$9.04M
2021-06-30$1.36M(m)-$2.77M

Revenue and expense 9 month

Period endResearch and developmentNet income
2025-09-30$7.77M-$16.18M
2024-09-30$5.12M-$10.33M
2023-09-30$10.51M-$16.60M
2022-09-30$7.06M-$13.07M
2021-09-30$7.15M-$18.06M

Revenue and expense 12 month

Period endResearch and developmentNet income
2025-12-31$9.77M-$22.45M
2024-12-31$9.45M-$16.56M
2023-12-31$15.49M-$23.53M
2022-12-31$9.00M-$17.68M
2021-12-31$8.41M-$20.71M
2020-12-31$5.09M-$7.18M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
OS Therapies Inc (OSTX)United States$0.076B-2.17
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
iBio, Inc. (IBIO)United States$0.077B-2.94